Skip to main content


Breast Cancer Research and Treatment

Breast Cancer Research and Treatment 3/2020

Ausgabe 3/2020

Inhaltsverzeichnis ( 26 Artikel )

19.11.2019 | Review | Ausgabe 3/2020

The prognostic value of NRF2 in breast cancer patients: a systematic review with meta-analysis

Micaela Almeida, Mafalda Soares, Ana Cristina Ramalhinho, José Fonseca Moutinho, Luiza Breitenfeld, Luísa Pereira

01.02.2020 | Review | Ausgabe 3/2020

Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis

Yan Li, Yidong Zhou, Feng Mao, Yan Lin, Xiaohui Zhang, Songjie Shen, Qiang Sun

08.11.2019 | Preclinical study | Ausgabe 3/2020 Open Access

HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies

Natasha Tracey, Helen Creedon, Alain J. Kemp, Jayne Culley, Morwenna Muir, Teresa Klinowska, Valerie G. Brunton

09.11.2019 | Preclinical study | Ausgabe 3/2020

Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer

Sasagu Kurozumi, Sami Alsaeed, Nnamdi Orah, Islam M. Miligy, Chitra Joseph, Abrar Aljohani, Michael S. Toss, Takaaki Fujii, Ken Shirabe, Andrew R. Green, Mohammed A. Aleskandarany, Emad A. Rakha

12.11.2019 | Preclinical study | Ausgabe 3/2020 Open Access

Tumor microenvironment and breast cancer survival: combined effects of breast fat, M2 macrophages and hyaluronan create a dismal prognosis

Satu Tiainen, Amro Masarwah, Sanna Oikari, Kirsi Rilla, Kirsi Hämäläinen, Mazen Sudah, Anna Sutela, Ritva Vanninen, Juho Ikonen, Raija Tammi, Markku Tammi, Päivi Auvinen

13.11.2019 | Preclinical study | Ausgabe 3/2020

Paget’s disease of the nipple in a Her2-positive breast cancer xenograft model

Katherine Drews-Elger, Ana Cristina Sandoval-Leon, Ayse Burcu Ergonul, Anna M. Jegg, Carmen Gomez-Fernandez, Philip C. Miller, Dorraya El-Ashry, Marc E. Lippman

19.11.2019 | Preclinical Study | Ausgabe 3/2020

The orphan nuclear receptor estrogen-related receptor beta (ERRβ) in triple-negative breast cancer

Aileen I. Fernandez, Xue Geng, Krysta Chaldekas, Brent Harris, Anju Duttargi, V. Layne Berry, Deborah L. Berry, Akanksha Mahajan, Luciane R. Cavalli, Balázs Győrffy, Ming Tan, Rebecca B. Riggins

25.11.2019 | Preclinical study | Ausgabe 3/2020

Spectrum and clinical relevance of PALB2 germline mutations in 7657 Chinese BRCA1/2-negative breast cancer patients

Yifan Wu, Tao Ouyang, Jinfeng Li, Tianfeng Wang, Zhaoqing Fan, Tie Fan, Benyao Lin, Ye Xu, Yuntao Xie

29.11.2019 | Preclinical study | Ausgabe 3/2020

Histone deacetylase (HDAC) inhibitors and doxorubicin combinations target both breast cancer stem cells and non-stem breast cancer cells simultaneously

Ling-Wei Hii, Felicia Fei-Lei Chung, Jaslyn Sian-Siu Soo, Boon Shing Tan, Chun-Wai Mai, Chee-Onn Leong

10.12.2019 | Preclinical study | Ausgabe 3/2020

TrkA overexpression in non-tumorigenic human breast cell lines confers oncogenic and metastatic properties

Kelly Kyker-Snowman, Robert M. Hughes, Christopher L. Yankaskas, Karen Cravero, Swathi Karthikeyan, Berry Button, Ian Waters, David Marc Rosen, Lauren Dennison, Natasha Hunter, Josh Donaldson, Eric S. Christenson, Konstantinos Konstantopoulos, Paula J. Hurley, Sarah Croessmann, Ben Ho Park

11.12.2019 | Preclinical study | Ausgabe 3/2020

Evaluation of the anti-Thomsen–Friedenreich antibodies Nemod-TF1 and Nemod-TF2 as prognostic markers in breast cancer

Sabine Heublein, Markus Egger, Junyan Zhu, Luisa Berger, Doris Mayr, Christian Schindlbeck, Christina Kuhn, Simone S. Hofmann, Florian Schuetz, Udo Jeschke, Nina Ditsch

01.02.2020 | Preclinical study | Ausgabe 3/2020

Amphiregulin deletion strongly attenuates the development of estrogen receptor-positive tumors in p53 mutant mice

David R. Meier, Megan A. Girtman, Kristopher A. Lofgren, Paraic A. Kenny

18.11.2019 | Clinical trial | Ausgabe 3/2020

Axillary lymph node dissection in node-positive breast cancer: are ten nodes adequate and when is enough, enough?

Laura H. Rosenberger, Yi Ren, Samantha M. Thomas, Rachel A. Greenup, Oluwadamilola M. Fayanju, E. Shelley Hwang, Jennifer K. Plichta

21.11.2019 | Clinical trial | Ausgabe 3/2020 Open Access

Results of a phase I, non-randomized study evaluating a Magnetic Occult Lesion Localization Instrument (MOLLI) for excision of non-palpable breast lesions

Nicole Look Hong, Frances C. Wright, Mark Semple, Alexandru M. Nicolae, Ananth Ravi

28.11.2019 | Clinical trial | Ausgabe 3/2020 Open Access

The influence on quality of life of intermittent scheduling in first- and second-line chemotherapy of patients with HER2-negative advanced breast cancer

Anouk K. M. Claessens, Reinier Timman, Jan J. Busschbach, Jeanette M. Bouma, Jeany M. Rademaker-Lakhai, Frans L. G. Erdkamp, Vivianne C. G. Tjan-Heijnen, Monique E. M. M. Bos, the Dutch Breast Cancer Research Group (BOOG)

06.12.2019 | Clinical trial | Ausgabe 3/2020

Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older

Min Hwan Kim, Gun Min Kim, Jee Hung Kim, Jee Ye Kim, Hyung Seok Park, Seho Park, Young Up Cho, Byeong Woo Park, Seung Il Kim, Joohyuk Sohn

09.11.2019 | Epidemiology | Ausgabe 3/2020

25-Hydroxyvitamin D at time of breast cancer diagnosis and breast cancer survival

Charlotte Kanstrup, Dorthe Teilum, Lars Rejnmark, Janne Villemoes Bigaard, Pia Eiken, Niels Kroman, Anne Tjønneland, Mathias Kvist Mejdahl

16.11.2019 | Epidemiology | Ausgabe 3/2020

Weight trajectories in women receiving systemic adjuvant therapy for breast cancer

Kirsten A. Nyrop, Allison M. Deal, Shlomit S. Shachar, Jihye Park, Seul Ki Choi, Jordan T. Lee, Erin A. O’Hare, Amy Wheless, Lisa A. Carey, Hyman B. Muss

18.11.2019 | Epidemiology | Ausgabe 3/2020 Open Access

Socioeconomic status differs between breast cancer patients treated with mastectomy and breast conservation, and affects patient-reported preoperative information

A. Frisell, J. Lagergren, M. Halle, J. de Boniface

21.11.2019 | Epidemiology | Ausgabe 3/2020

Exome sequencing study of Russian breast cancer patients suggests a predisposing role for USP39

Ekaterina S. Kuligina, Anna P. Sokolenko, Ilya V. Bizin, Alexandr A. Romanko, Kirill A. Zagorodnev, Maria O. Anisimova, Daria D. Krylova, Elena I. Anisimova, Maria A. Mantseva, Ashok K. Varma, Syed K. Hasan, Valeria I. Ni, Andrey V. Koloskov, Evgeny N. Suspitsin, Aigul R. Venina, Svetlana N. Aleksakhina, Tatiana N. Sokolova, Ana Marija Milanović, Peter Schürmann, Darya S. Prokofyeva, Marina A. Bermisheva, Elza K. Khusnutdinova, Natalia Bogdanova, Thilo Dörk, Evgeny N. Imyanitov

26.11.2019 | Epidemiology | Ausgabe 3/2020

Pre- and post-diagnostic intake of whole grain and dairy products and breast cancer prognosis: the Danish Diet, Cancer and Health cohort

Julie Louise Munk Andersen, Louise Hansen, Birthe Lykke Riegels Thomsen, Lisa Rudolph Christiansen, Lars Ove Dragsted, Anja Olsen

27.11.2019 | Epidemiology | Ausgabe 3/2020

Breast density measured volumetrically in a clinical environment: cross-sectional study with photon counting technology

Jean L. Browne, Lilian Casas, Guillermo Santandreu, Ignacio Rodriguez, Beatriz Navarro, Francesc Tresserra, M. Angela Pascual

01.02.2020 | Letter to the Editor | Ausgabe 3/2020

Do multifocal or multicentric pT1a node-negative HER2+ breast cancers get benefit from systemic treatment?

Kadri Altundag

01.02.2020 | Letter to the Editor | Ausgabe 3/2020

Proper treatment of breast angiosarcoma-mastectomy or breast conserving surgery?

Darko Zdravkovic, Miroslav Granic, Bogdan Crnokrak

01.02.2020 | Letter to the Editor | Ausgabe 3/2020

Re: Association of depression and anxiety disorder with the risk of mortality in breast cancer

Hong-Lin Chen, Lin Du, Xiao-Min Li

16.11.2019 | Correction | Ausgabe 3/2020 Open Access

Correction to: Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy

Suzanne E. Wardell, Alexander P. Yllanes, Christina A. Chao, Yeeun Bae, Kaitlyn J. Andreano, Taylor K. Desautels, Kendall A. Heetderks, Jeremy T. Blitzer, John D. Norris, Donald P. McDonnell

Aktuelle Ausgaben

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.